Medical policy governing coverage and medical necessity of proton beam radiation therapy for members in the state of Ohio; applies to adults (19+) with special rules for individuals under 19. Providers and reviewers in Ohio are affected.
Change TypeRevised coverage stanceadded exception pathway language
Effective DateAug 1, 2025
Next Review Date
Key ActionSubmit prior authorization with documentation showing normal tissue cannot be spared by standard techniques and include comparative PBT, IMRT, and SBRT treatment plans.
Revised language to indicate proton beam radiation therapy (PBT) is unproven and not medically necessary due to insufficient evidence of efficacy for treating all other indications not listed in the policy as proven and medically necessary, including glioma and retroperitoneal sarcoma.
Requests for exceptions will be evaluated on a case-by-case basis when documentation shows normal tissue sparing cannot be achieved with standard radiation techniques and includes comparison treatment plans for PBT, IMRT, and SBRT.
Updated Clinical Evidence and References sections to reflect the most current information.
19+Applies to age
OhioState
ProstateProven indication
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Case-by-caseException allowed
glioma, RPSExamples unproven
RequiredPrior auth
Coverage and Medical Necessity Criteria
General Coverage Stance
Covered when ALL of the following apply:
Pediatric Coverage: Proton beam radiation therapy is covered without further review for individuals younger than 19 years of age.age < 19
Policy applies to individuals younger than 19 (covered without further review)
Adult Coverage — General: Proton beam radiation therapy may be considered proven and medically necessary under certain circumstances for adults (>= 19 years) when medical necessity criteria are met per InterQual CP: Procedures, Proton Beam Radiotherapy (PBRT).age >= 19 and InterQual criteria met
Refer to InterQual for clinical coverage criteria
Equivalence for Prostate Cancer: For clinically localized prostate cancer (up to T3, N0M0), PBT and IMRT are considered clinically equivalent; if InterQual cannot determine medical necessity, principles of medical necessity will be applied and PBT may be considered proven for prostate cancer based on cited evidence and guideline statements.localized prostate cancer and InterQual/guideline considerations
AUA/ASTRO and NCCN statements support PBT as an option but do not show superiority
Limitations for Other Adult Indications: PBT is unproven and not medically necessary for treating adult indications not listed as proven in this policy (examples include glioma and retroperitoneal sarcoma) unless exception criteria are met.other adult indications without supportive evidence
See exception pathway for documentation requirements
Covered with contextual criteria (guideline-conditional indications)
Covered with contextual criteria — PBT may be considered in select indications when guideline-based considerations or toxicity‑mitigation rationales apply:
Prostate cancer: PBT may be considered an option for clinically localized prostate cancer; guidelines (AUA/ASTRO, NCCN) describe PBT as a conditional or reasonable alternative but do not demonstrate superiority over photon techniques; comparative evidence reports mixed toxicity findings (some population studies show greater long‑term GI toxicity with PBT vs IMRT).clinically localized prostate cancer (T1–T3 N0M0)
Document guideline-based rationale when used as alternative to photons
Central nervous system (CNS) tumors: When toxicity to critical OARs is a concern (e.g., IDH‑mutant WHO grade 2–3 diffuse glioma, spinal ependymoma, medulloblastoma), professional guidance conditionally recommends considering PBT to reduce acute and late toxicity if available.tumor adjacent to critical OARs or high risk of neurocognitive/late toxicity
ASTRO and NCCN conditional recommendations support consideration
Guideline-based conditional indications
Guideline-based conditional indications — professional guidelines conditionally recommend or consider PBT in the following scenarios:
ASTRO conditional recommendation: ASTRO conditionally recommends proton therapy as an option to reduce acute and late toxicity for IDH‑mutant WHO grade 2 and 3 diffuse glioma, particularly when tumors are near critical organs at risk.tumor adjacent to OARs
ASTRO guideline (Halasz et al., 2022)
NCCN CNS statements: NCCN indicates PBT should be considered if available when toxicity is a concern for spinal ependymoma or medulloblastoma and may be conditionally considered for select gliomas to spare uninvolved brain and preserve cognitive function.toxicity concern or good long‑term prognosis
NCCN CNS guidance (2024)
NCCN esophageal guidance: NCCN states PBT is appropriate for esophageal and esophagogastric junction cancers when dose reduction to OARs cannot be achieved with 3D‑CRT and recommends clinical trial enrollment when data are evolving.
Evidence summaries by tumor site
Evidence summaries by tumor site — summaries of comparative evidence that may support or limit coverage decisions:
Breast cancer: Systematic reviews/meta‑analyses suggest PBT can reduce heart and lung doses and may reduce some toxicities; evidence quality is low, no RCTs directly comparing PBT to photon RT exist, and additional high‑quality trials are needed.
Holt et al. 2023; Hayes assessments
Esophageal cancer: Meta‑analyses and HTAs report PBT reduces OAR doses and some toxicities versus photon RT and may improve prognosis in some analyses; however, evidence is heterogeneous, largely low quality, and NCCN recommends trial enrollment when feasible.
Zhou et al. 2023; Hayes assessments
Gastrointestinal (rectal and other GI) cancers: Dosimetric data consistently show reduced bowel/bladder/pelvic bone marrow exposure with PBT versus photons, but clinical outcome data are insufficient to establish superiority; more RCTs are required.
Le et al. 2024; Fok et al. 2021; Verma et al. 2016b
Site-specific evidence summaries
Site-specific evidence summaries — key findings and limitations by tumor type:
Gynecologic cancers: Prospective uncontrolled series (e.g., 25 patients) reported five‑ and ten‑year survival comparable to conventional therapies with some severe late complications; ongoing trials exist but NCCN does not address PBT for gynecologic cancers.
Kagei et al.; NCCN
Head & neck cancers: Evidence is mixed and mostly retrospective; practice parameters note PBRT can minimize dose to critical head and neck structures potentially improving QOL, but NCCN provides limited endorsement across many HNC subsites.
Hayes report; ACR/ARS practice parameter; NCCN
Non‑small cell lung cancer (NSCLC): Randomized and single‑arm studies show mixed results: a randomized trial (PSPT vs IMRT) found no difference in local failure and mixed pneumonitis rates; other series report promising toxicity and local control but no definitive phase III evidence—charged particle therapy is considered experimental by some reviews until higher‑quality data are available.
Liao et al. 2018; Chang 2017; systematic reviews
Unproven and Not Medically Necessary / Exception Criteria
Policy stance on unproven indications and the exception pathway:
Unproven / Not Medically Necessary — General: Proton beam radiation therapy is considered unproven and not medically necessary for all adult indications not listed in this policy as proven and medically necessary due to insufficient evidence of efficacy (examples cited include glioma and retroperitoneal sarcoma).adult indications not otherwise proven
Policy revised to clarify unproven status for these indications
Exception Consideration Conditions: Both of the following must be documented for an exception to be considered: (1) Sparing of the surrounding normal tissue cannot be achieved with standard radiation therapy techniques; AND (2) Evaluation includes a comparison of treatment plans for PBT, IMRT, and SBRT for the specific individual.both conditions required
When both conditions are met, PBT may be covered for selected cases such as recurrences or metastases; requests evaluated case‑by‑case
Proton beam radiation therapy (PBT) is considered unproven and not medically necessary for adult indications not specifically listed as proven and medically necessary in this policy (for example, glioma and retroperitoneal sarcoma). Exception requests may be considered on a case‑by‑case basis only when documentation demonstrates both that sparing of surrounding normal tissue cannot be achieved with standard radiation therapy techniques and that a formal comparison of treatment plans for PBT, IMRT, and SBRT for the individual has been provided.
Radiation therapy, including PBT, is not recommended for neovascular age‑related macular degeneration (AMD) because systematic reviews and randomized trials have not demonstrated consistent clinical benefit and have shown risks of vision loss and other adverse effects. The American Academy of Ophthalmology states that RT has insufficient data to demonstrate clinical efficacy, and use of proton beam or other radiation modalities for neovascular AMD would be considered not medically necessary pending higher‑quality evidence.
The National Comprehensive Cancer Network (NCCN) does not currently address routine use of PBT for several tumor sites, including breast, gastric, and gynecologic cancers. Absence of NCCN guidance for these indications indicates a lack of guideline endorsement for routine PBT use and supports the policy position that PBT is not established for these sites outside of investigational settings or individualized exception review.
Charged particle therapy (including PBT) for lung cancer is considered experimental until higher‑quality phase III evidence is available. Systematic reviews and historical series show encouraging local control and dosimetric advantages, but no definitive phase III data currently establish superiority over photon approaches; requests for PBT in lung cancer should be evaluated in light of this evidence gap.
There is no clinical evidence supporting delivery of proton beam therapy combined with IMRT within a single treatment plan. The literature search identified no studies endorsing combined PBT+IMRT planning or delivery, and combined use is not supported by current clinical evidence.
Overall, PBT is regarded as unproven and not medically necessary for many adult indications because of insufficient evidence of efficacy. When requests fall outside the policy's proven indications, coverage may be considered only as an exception when the required documentation and comparative treatment plans are provided, and when standard photon techniques cannot achieve necessary normal tissue sparing.
Professional ophthalmology guidance and systematic reviews do not support proton beam radiation for neovascular AMD. Trials and reviews report uncertain or negative effects on visual outcomes and note significant methodological limitations; the American Academy of Ophthalmology explicitly states radiation therapy has insufficient data to demonstrate efficacy for AMD and does not recommend it.
Multiple systematic reviews, technology assessments, and meta‑analyses conclude that the overall quality of evidence comparing PBT to photon radiotherapy is low or insufficient for many tumor sites. Dosimetric advantages are frequently reported, but high‑quality randomized data demonstrating clinical superiority are generally lacking, limiting routine coverage outside of specified indications or clinical trials.
For lung cancer, charged particle therapy remains experimental pending results from higher‑quality phase III trials. Systematic reviews identified no phase III trials and emphasized the need for randomized data to justify routine adoption; ongoing phase III studies are noted but have not yet resolved the evidence gap.
Requests proposing combined delivery of PBT and IMRT in a single treatment plan should be denied or deemed unsupported because the clinical literature contains no evidence validating combined PBT+IMRT planning or demonstrating clinical benefit for such combined approaches.
Procedure, HCPCS, and Diagnosis Codes
Procedure Codes (PBT and related RT services)CPT
77301
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387
Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77520
Proton treatment delivery; simple, without compensation.
77522
Proton treatment delivery; simple, with compensation.
77523
Proton treatment delivery; intermediate.
77525
Proton treatment delivery; complex.
HCPCS/G-codesHCPCS
G6015
Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016
Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session.
G6017
Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment.
Representative Diagnosis Codes (ICD-10)ICD-10
C11.0
Malignant neoplasm of superior wall of nasopharynx.
C22.0
Liver cell carcinoma.
C61
Malignant neoplasm of prostate.
C69.6
Malignant neoplasm of orbit.
D09.20
Carcinoma in situ of unspecified eye.
Q28.2
Arteriovenous malformation of cerebral vessels.
Age
Age applicabilityPolicy applies to individuals 19 years of age and older; individuals younger than 19 are covered without further review.
Pediatric coverage noteProton beam radiation therapy (PBRT/PBT) is covered without further review for individuals younger than 19 years of age.
Reference for medical necessity criteriaFor adult medical necessity clinical coverage criteria, refer to InterQual CP: Procedures, Proton Beam Radiotherapy (PBRT).
Prior Authorization, Documentation, and Review Guidance
Prior Authorization
Prior authorization and justification for esophageal cancer
Prior authorization is required for proton beam therapy (PBT). Requests for esophageal cancer must include documentation that dose reduction to organs at risk (OARs) is necessary and cannot be achieved with standard photon techniques (e.g., 3D-CRT, IMRT). When clinical necessity is claimed, include a comparison of treatment plans (PBT vs IMRT and, when relevant, SBRT) demonstrating expected OAR sparing with PBT.
Affected codes: see Applicable Codes section of policy (reference only).
Clinical trial NCT03801876 recruiting for photon vs proton in esophageal cancer.
Prior Authorization
Prior authorization: clinical necessity
All PBT requests must demonstrate clinical necessity for the individual patient. Provide disease site, stage, prior treatments, and a clear rationale why conventional photon therapy is insufficient to meet treatment goals or minimize toxicity. For indications with guideline support (e.g., select CNS, Hodgkin/lymphoma, NSCLC in select circumstances), reference the applicable guideline recommendations.
Include tumor location, expected target volumes, and specific OARs at risk.
Background and Rationale
Proton beam therapy uses charged protons that deposit most of their energy near the end of their path (the Bragg peak), allowing more focal dose delivery compared with photon external beam radiation therapy. This physical characteristic can reduce dose to tissues beyond the tumor and spare adjacent normal organs at risk, which is the principal rationale for selecting PBT when normal‑tissue sparing is clinically necessary.
Key Definitions
PBT definition
TermProton beam radiation therapy (PBT)
MechanismUses charged protons (positively charged particles) that deposit most energy within the tumor region, delivering minimal dose beyond tumor boundaries (Bragg peak).
Intended benefitDesigned to deliver more targeted radiation to tumor tissue with less collateral dose to surrounding healthy tissues compared with photon EBRT.
Clinical contextUsed for several adult solid tumors and certain pediatric cancers, though evidence of clear clinical superiority over EBRT is limited for many adult indications.
Clinically localized prostate cancer definition
DefinitionClinically localized prostate cancer: up to clinical stage T3 prostate cancer without nodal or distant metastasis (N0M0) on conventional imaging.
Policy Revision History
2025-08-01policy_revisionLatest
Revised Coverage Rationale to state proton beam radiation therapy (PBT) is unproven and not medically necessary for indications not listed as proven and medically necessary (examples: glioma, retroperitoneal sarcoma); clarified that PBT may be covered for selected recurrences or metastases when documented criteria are met.
2025-08-01exception_criteria_added
Added exception evaluation criteria requiring (1) documentation that sparing of surrounding normal tissue cannot be achieved with standard radiation therapy techniques and (2) inclusion of comparative treatment plans for PBT, IMRT, and SBRT for the individual.
Change TypeRevised coverage stanceadded exception pathway language
Effective DateAug 1, 2025
Next Review Date
Key ActionSubmit prior authorization with documentation showing normal tissue cannot be spared by standard techniques and include comparative PBT, IMRT, and SBRT treatment plans.
Esophageal / esophagogastric junction cancers: NCCN states PBT is appropriate when dose reduction to OARs is necessary and cannot be achieved with 3D‑CRT; because the evidence is evolving, NCCN recommends use within clinical trials when feasible and documentation that photon techniques cannot meet OAR constraints is expected.OAR dose reduction necessary and photon techniques insufficient
Prior authorization should document inability to meet constraints with photon RT
Age‑related macular degeneration (AMD): Evidence does not support routine use of radiation (including PBT) for neovascular AMD; systematic reviews and guideline statements conclude insufficient data and potential for adverse outcomes, so PBT is not recommended for AMD outside trials.neovascular AMD
AAO statements and systematic reviews report uncertain benefit and potential harms
Bladder cancer and other emerging sites: For muscle‑invasive bladder cancer and other sites with limited data, PBT may be reported in small series but lacks robust long‑term comparative evidence; consideration is contingent on case specifics and supporting documentation that PBT provides meaningful OAR sparing not achievable with photon approaches.select cases with demonstrated dosimetric/clinical rationale
Registry and small cohort data exist but long‑term validation is needed
OAR dose reduction required and photon methods insufficient
NCCN guidance (2024)
Gynecologic cancers: Limited prospective uncontrolled data (e.g., small cervical cancer series) show survival comparable to historical controls but with some late complications; NCCN does not currently address PBT for gynecologic malignancies.
Kagei et al. 2003; NCCN statements
Lymphomas: Small, lower‑quality studies show encouraging early outcomes with potential to reduce long‑term toxicity; NCCN states PBT may be appropriate depending on circumstances to spare OARs.
Multiple small studies; NCCN guidance
Pancreatic cancer: Robust clinical evidence is lacking; ongoing research continues and NCCN does not address PBT for pancreatic adenocarcinoma.
Limited studies; ongoing trials
Vestibular schwannoma (VS): Meta‑analysis shows high tumor control (~95%) but limited hearing preservation (~40.6%) and no demonstrated advantage over standard stereotactic radiosurgery for facial/hearing outcomes; comparative data are insufficient to support superior functional outcomes.
Santacroce et al. 2023; critical reviews
Documentation Expectations for Exceptions:
Exception requests must include clinical rationale and plan comparisons demonstrating that photon or other conformal techniques cannot achieve necessary OAR sparing; supporting evidence such as dosimetric comparisons and relevant guideline/trial references should be provided.
detailed documentation and plan comparisons
Requests lacking required documentation or comparative plans may be denied
Combination Therapy Limitation: Combined use of PBT and IMRT in a single treatment plan is not supported by the clinical literature and is not endorsed.
No evidence identified supporting combined PBT+IMRT plans
If InterQual criteria apply, reference InterQual output and how the case meets those criteria.
Prior Authorization
Prior authorization / exception evaluation
Exception requests are evaluated case-by-case. Exceptions may be considered only when documentation shows that standard photon techniques cannot achieve necessary normal tissue sparing and when paired plan comparisons support PBT benefit.
Exceptions require both: documentation of inability to spare surrounding normal tissue with standard techniques; and a comparison of PBT, IMRT, and SBRT plans for the individual.
Provide clinical justification referencing guidelines or investigational rationale if applicable.
Denial Risk
Prostate toxicity concerns
For prostate cancer, highlight and document potential GI toxicity concerns. If InterQual criteria do not clearly establish medical necessity, note that PBT and IMRT are considered clinically equivalent for prostate cancer; apply principles of medical necessity and provide justification if requesting PBT over IMRT.
Document prior lower GI or GU morbidity, anatomy or comorbidities increasing risk, and reasons photon therapy cannot adequately mitigate risk.
Reference ongoing trials (NCT01617161, NCT00969111, NCT03561220) when discussing evolving evidence.
Note
Clinical trial preference for evolving indications
When indications are evolving and evidence is limited, enrollment in a clinical trial is preferred. If the patient is not enrolled, provide strong clinical justification and plan comparison data demonstrating expected benefit of PBT over photon therapy.
List of relevant trials should be provided when available and applicable to the case.
For esophageal cancer and other evolving indications, indicate whether a suitable trial (e.g., NCT03801876) exists and if the patient is eligible.
Denial Risk
Exception criteria not met
If exception criteria are not met, PBT will be considered unproven and not medically necessary for that indication. Denials will reference insufficient evidence of superiority and absence of documented inability to achieve OAR sparing with photon techniques.
Include clear statement of which exception criteria were not satisfied in the denial rationale.
Advise providers on appeals process and what additional documentation would be considered.
Documentation Required
Documentation required for exception requests
Required documentation for exception requests should be submitted with the prior authorization. Incomplete submissions may delay review or result in denial.
Clinical summary including diagnosis, stage, prior treatments, and treatment intent (curative/palliative).
Comparative treatment plans (PBT, IMRT, and SBRT when relevant) with dose–volume histograms (DVHs) and projected OAR doses.
Radiology and operative reports, relevant pathology, and prior radiation records if applicable.
If claiming superiority based on anatomy or comorbidity, include imaging (CT/MRI/PET) showing tumor/OAR relationships and a narrative explaining why photon plans cannot meet OAR constraints.
Documentation Required
OAR and toxicity justification
Provide OAR-specific justification and anticipated toxicity reduction. Include quantitative plan comparisons (e.g., DVH metrics) that demonstrate clinically meaningful decreases in dose to critical structures and explain the clinical significance of those reductions.
Identify specific OARs of concern (e.g., heart, lungs, spinal cord, bowel, salivary glands) and provide dose constraints used.
Describe expected reduction in acute and late toxicity with supporting plan data.
Documentation Required
Trial enrollment or justification documentation
If a clinical trial is not feasible, provide documentation of trial screening/enrollment efforts or rationale for ineligibility. Detail why trial participation was not possible and why standard-of-care photon therapy is inadequate for the patient.
Evidence of trial screening or correspondence with trial coordinators where applicable.
If declined by patient, document informed consent discussion and reasons.
Prior Authorization
Consideration of alternative conformal RT prior to PBT
Prior to approving PBT, consider a trial of advanced conformal photon therapy (IMRT/VMAT/IGRT) where clinically appropriate. Documentation should show either a trial of photon therapy with unacceptable toxicity or that photon techniques cannot achieve required OAR sparing.
When practical, supply prior photon treatment records and outcomes or explicit planning comparisons showing photon limitations.
For CNS, thoracic, and head & neck sites, document attempts at conformal photon planning if undertaken.
Billing Rule
Combined therapy limitation
Combined modality constraints: concurrent or sequential use of PBT with other modalities (e.g., surgery, chemotherapy, photon boost) may affect coverage decisions. Provide full treatment sequencing, rationale, and how combined therapy impacts OAR dosing and toxicity.
If PBT is requested as a boost after photon therapy or combined with X-rays, include plan comparisons showing net benefit.
Specify whether combination therapy is part of a clinical trial or standard-of-care regimen.
Guideline contextAUA/ASTRO systematic review (2022) targeted this population and conditionally recommended proton therapy as a treatment option but did not find superiority over other radiation modalities.
Implication for coverageWhen InterQual criteria cannot determine medical necessity, guideline considerations for clinically localized (T1–T3 N0M0) prostate cancer are applied per policy.
OAR definition
TermOAR (Organ At Risk)
DefinitionCritical normal structures where dose sparing is clinically important and a rationale for selecting proton therapy may be provided to reduce acute or late toxicity.
Policy relevanceRequests citing OAR-sparing as the rationale should document tumor location relative to OARs and show why photon techniques cannot achieve acceptable constraints.
OARs (alternate entry)
Alternate phrasingOrgans at risk (OARs): critical normal tissues adjacent to the treatment target where dose reduction is desirable to limit toxicity.
Examples and useWhen toxicity is a concern (e.g., spinal ependymoma, medulloblastoma, diffuse gliomas near critical structures), NCCN/ASTRO note PBT may be considered to spare OARs.
Authorization implicationDocumentation should demonstrate that acceptable OAR constraints cannot be met with standard photon techniques to support exception requests.
Relative biologic effectiveness (RBE)
DefinitionRelative biologic effectiveness (RBE)
MeaningRBE is the absorbed Gray (Gy) dose multiplied by the relative biologic effectiveness factor for protons; dose reporting in proton studies may use Gy RBE.
Example from evidenceIn lung cancer trials, lung and heart dose comparisons are reported in Gy RBE to account for proton biological effectiveness differences versus photons.
Vestibular schwannoma (VS)
DefinitionVestibular schwannoma (VS)
Clinical descriptionA benign tumor of the vestibular (acoustic) nerve for which multiple radiotherapeutic options exist, including single-session stereotactic radiosurgery (SRS), fractionated conventional RT, fractionated stereotactic RT, and proton beam therapy.
Evidence summarySystematic reviews and institutional series report high tumor control rates (~91–100%) with PBT but variable and generally lower hearing preservation rates (reported ~33–42%), and no comparative studies were identified to determine outcome advantages versus other modalities.
2025-08-01
supporting_information_updated
Updated Clinical Evidence and References sections to reflect current information and archived previous policy version CS105OH.C.